VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
CORCencora, Inc.
$271.83$52.9B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

COR logoCencora, Inc.(COR)Earnings, Financials & Key Ratios

COR•NYSE
34.1× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustryMedical DistributionSub-IndustryDrug Wholesalers and Distributors
AboutCencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.Show more
  • Revenue$321.33B+9.3%
  • EBITDA$4.71B+13.3%
  • Net Income$1.55B+3.0%
  • EPS (Diluted)7.96+5.7%
  • Gross Margin3.16%+6.6%
  • EBITDA Margin1.46%+3.7%
  • Operating Margin1.14%+9.8%
  • Net Margin0.48%-5.8%
  • ROE122.67%-40.9%

COR Key Insights

Cencora, Inc. (COR) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Excellent 3Y average ROE of 267.9%
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 11.1%
  • ✓Share count reduced 2.5% through buybacks
  • ✓Efficient asset utilization: 4.2x turnover

✗Weaknesses

  • ✗High debt to equity ratio of 6.2x
  • ✗Thin 5Y average net margin of 0.6%
  • ✗Expensive at 30.4x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when COR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

COR Price & Volume

Cencora, Inc. (COR) stock price & volume — 10-year historical chart

Loading chart...

COR Growth Metrics

Cencora, Inc. (COR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years8.98%
5 Years11.09%
3 Years10.43%
TTM5.95%

Profit CAGR

10 Years-
5 Years-
3 Years-2.92%
TTM50.51%

EPS CAGR

10 Years-
5 Years-
3 Years-0.33%
TTM51.33%

Return on Capital

10 Years20.99%
5 Years20.69%
3 Years21.41%
Last Year23.09%

COR Recent Earnings

Cencora, Inc. (COR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (91%)●Beat Revenue 7/12 qtrs (64%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$4.75-1.5%
$4.82
Rev
$78.4B-3.4%
$81.1B
Q1 2026
Feb 4, 2026
Metric
Actual
Est
EPS
$4.08+0.7%
$4.05
Rev
$85.9B-0.1%
$86.1B
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$3.84+1.3%
$3.79
Rev
$83.7B+0.3%
$83.5B
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$4.00+3.9%
$3.85
Rev
$80.7B+0.7%
$80.1B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$4.75vs $4.82-1.5%
$78.4Bvs $81.1B-3.4%
Q1 2026Feb 4, 2026
$4.08vs $4.05+0.7%
$85.9Bvs $86.1B-0.1%
Q4 2025Nov 5, 2025
$3.84vs $3.79+1.3%
$83.7Bvs $83.5B+0.3%
Q3 2025Aug 6, 2025
$4.00vs $3.85+3.9%
$80.7Bvs $80.1B+0.7%
Based on last 12 quarters of dataView full earnings history →

COR Peer Comparison

Cencora, Inc. (COR) competitors in Drug Wholesalers and Distributors — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
MCK logoMCKMcKesson CorporationDirect Competitor90.23B750.6319.5612.36%1.18%
CAH logoCAHCardinal Health, Inc.Direct Competitor52.19B221.7734.38-1.87%0.62%
OMI logoOMIOwens & Minor, Inc.Product Competitor171.11M2.24-0.16-74.19%-39.85%-21.12%
HSIC logoHSICHenry Schein, Inc.Product Competitor9.17B79.9224.444.03%3.02%8.24%0.77
CVS logoCVSCVS Health CorporationSupply Chain125.45B98.3270.737.85%0.72%3.86%1.24
PBM logoPBMPsyence Biomedical Ltd.Supply Chain20.53M3.15-0.40-43.78%
UNH logoUNHUnitedHealth Group IncorporatedSupply Chain363.94B400.9630.3111.81%2.68%11.54%0.77
CI logoCICigna CorporationSupply Chain73.63B279.2712.6011.26%2.26%15.08%0.75

Compare COR vs Peers

Cencora, Inc. (COR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MCK

Most directly comparable listed peer for COR.

Scale Benchmark

vs UNH

Larger-name benchmark to compare COR against a more recognizable public peer.

Peer Set

Compare Top 5

vs MCK, CAH, OMI, HSIC

COR Income Statement

Cencora, Inc. (COR) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricSep'17Sep'18Sep'19Sep'20Sep'21Sep'22Sep'23Sep'24Sep'25TTM
Sales/Revenue
153.14B167.94B179.59B189.89B213.99B238.59B262.17B293.96B321.33B328.68B
Revenue Growth %
4.29%9.66%6.94%5.74%12.69%11.5%9.89%12.12%9.31%5.95%
Cost of Goods Sold
149B163.83B175.06B185.1B207.72B230.99B254.42B285.26B311.19B317.02B
COGS % of Revenue
97.29%97.55%97.48%97.48%97.07%96.81%97.04%97.04%96.84%-
Gross Profit
4.15B▲ 0%
4.11B▼ 0.9%
4.53B▲ 10.2%
4.79B▲ 5.8%
6.27B▲ 30.8%
7.6B▲ 21.2%
7.76B▲ 2.1%
8.7B▲ 12.2%
10.14B▲ 16.6%
11.66B▲ 0%
Gross Margin %
2.71%2.45%2.52%2.52%2.93%3.19%2.96%2.96%3.16%3.55%
Gross Profit Growth %
9.88%-0.86%10.19%5.78%30.83%21.24%2.05%12.18%16.55%-
Operating Expenses
2.13B2.46B2.66B2.77B3.59B4.85B5.31B5.66B6.49B7.66B
OpEx % of Revenue
1.39%1.47%1.48%1.46%1.68%2.03%2.03%1.93%2.02%-
Selling, General & Admin
2.13B2.46B2.66B2.77B3.59B4.85B5.31B5.66B6.49B7.19B
SG&A % of Revenue
1.39%1.47%1.48%1.46%1.68%2.03%2.03%1.93%2.02%-
Research & Development
0000000000
R&D % of Revenue
----------
Other Operating Expenses
0000000001000K
Operating Income
2.02B▲ 0%
1.65B▼ 18.2%
1.87B▲ 13.1%
2.02B▲ 8.5%
2.68B▲ 32.1%
2.75B▲ 2.9%
2.45B▼ 11.1%
3.04B▲ 24.3%
3.65B▲ 20.0%
4B▲ 0%
Operating Margin %
1.32%0.98%1.04%1.07%1.25%1.15%0.93%1.03%1.14%1.22%
Operating Income Growth %
19.93%-18.2%13.06%8.47%32.13%2.87%-11.09%24.26%19.98%-
EBITDA
2.44B2.15B2.36B2.43B3.18B3.45B3.42B4.15B4.71B5.03B
EBITDA Margin %
1.59%1.28%1.31%1.28%1.49%1.45%1.3%1.41%1.46%1.53%
EBITDA Growth %
18.05%-11.9%9.51%3.02%31.08%8.47%-0.89%21.44%13.35%17.38%
D&A (Non-Cash Add-back)
422.92M499.64M488.54M401.62M505.17M697.94M972.39M1.11B1.06B1.03B
EBIT
1.07B1.37B1.16B-5.14B2.4B2.42B2.44B2.25B2.68B1.72B
Net Interest Income
-145.19M-174.7M-157.77M-137.88M-174.07M-210.67M-228.93M-156.99M-291.55M-372.5M
Interest Income
3.86M14.94M37.7M20.64M8.47M21.31M46.72M91.69M128.21M87.58M
Interest Expense
149.04M189.64M195.47M158.52M182.54M231.98M275.65M248.68M419.75M460.08M
Other Income/Expense
-1.1B-473.53M-899.42M-7.32B-453.15M-568.62M-285.68M-1.04B-1.39B-492.65M
Pretax Income
917.89M▲ 0%
1.18B▲ 28.3%
967.11M▼ 17.9%
-5.29B▼ 647.4%
2.22B▲ 142.0%
2.18B▼ 1.7%
2.16B▼ 1.0%
2B▼ 7.3%
2.26B▲ 12.7%
3.51B▲ 0%
Pretax Margin %
0.6%0.7%0.54%-2.79%1.04%0.92%0.82%0.68%0.7%1.07%
Income Tax
553.4M-438.47M112.97M-1.89B677.25M516.52M428.26M484.7M690.52M954.11M
Effective Tax Rate %
60.29%-37.24%11.68%35.78%30.48%23.66%19.82%24.19%30.58%27.21%
Net Income
414.48M▲ 0%
1.66B▲ 300.1%
855.37M▼ 48.4%
-3.4B▼ 497.4%
1.54B▲ 145.3%
1.7B▲ 10.3%
1.75B▲ 2.7%
1.51B▼ 13.5%
1.55B▲ 3.0%
2.55B▲ 0%
Net Margin %
0.27%0.99%0.48%-1.79%0.72%0.71%0.67%0.51%0.48%0.78%
Net Income Growth %
-70.97%300.11%-48.42%-497.44%145.3%10.32%2.74%-13.53%2.99%50.51%
Net Income (Continuing)
364.48M1.62B854.13M-3.4B1.54B1.67B1.73B1.52B1.57B2.56B
Discontinued Operations
0000000000
Minority Interest
0117.14M114.29M179.29M361.06M282.83M144.28M140.8M239.07M187.36M
EPS (Diluted)
1.64▲ 0%
7.53▲ 359.1%
4.04▼ 46.3%
-16.60▼ 510.9%
7.39▲ 144.5%
8.04▲ 8.8%
8.53▲ 6.1%
7.53▼ 11.7%
7.96▲ 5.7%
13.04▲ 0%
EPS Growth %
-74.05%359.15%-46.35%-510.89%144.52%8.8%6.09%-11.72%5.71%51.33%
EPS (Basic)
1.677.614.07-16.607.488.158.627.608.02-
Diluted Shares Outstanding
221.6M220.34M211.84M204.78M208.47M211.21M204.59M200.28M195.21M195.38M
Basic Shares Outstanding
218.38M217.87M210.16M204.78M205.92M208.47M204.59M198.5M193.82M194.54M
Dividend Payout Ratio
77.27%20.08%39.63%-23.81%23.06%22.85%27.58%28.12%-

COR Balance Sheet

Cencora, Inc. (COR) balance sheet — assets, liabilities & shareholders' equity

MetricSep'17Sep'18Sep'19Sep'20Sep'21Sep'22Sep'23Sep'24Sep'25TTM
Total Current Assets
24.3B25.89B28.13B33.02B38.8B39.59B42.8B47.72B52.24B53.14B
Cash & Short-Term Investments
2.44B2.49B3.37B4.6B2.55B3.53B2.69B3.23B4.39B2.24B
Cash Only
2.44B2.49B3.37B4.6B2.55B3.53B2.69B3.23B4.39B2.24B
Short-Term Investments
0000000000
Accounts Receivable
10.3B11.31B12.39B14.3B18.39B18.63B20.91B23.87B25.23B24.89B
Days Sales Outstanding
24.5624.5925.1827.4831.3728.4929.1129.6428.6527.95
Inventory
11.46B11.92B11.06B12.59B15.37B17.09B17.45B19B20.49B20.01B
Days Inventory Outstanding
28.0826.5523.0624.82272725.0424.3124.0424.39
Other Current Assets
118.56M169.12M1.31B1.53B2.13B342.89M1.84B1.71B2.13B6B
Total Non-Current Assets
11.01B11.78B11.04B11.22B18.54B16.97B19.76B19.38B24.35B28.51B
Property, Plant & Equipment
1.8B1.89B1.77B1.93B3.23B3.08B3.15B3.32B4.09B2.81B
Fixed Asset Turnover
85.18x88.74x101.43x98.48x66.25x77.46x83.11x88.46x78.61x111.65x
Goodwill
6.04B6.66B6.71B6.71B9.03B8.5B9.57B9.32B13.68B16.45B
Intangible Assets
2.83B2.95B2.29B1.89B5.26B4.33B4.43B4B3.77B6.05B
Long-Term Investments
57.6M0-1.86B0060.37M63.12M66.64M00
Other Non-Current Assets
280.06M270.94M269.07M336.33M726.81M756.32M2.34B2.43B2.6B3.01B
Total Assets
35.32B▲ 0%
37.67B▲ 6.7%
39.17B▲ 4.0%
44.27B▲ 13.0%
57.34B▲ 29.5%
56.56B▼ 1.4%
62.56B▲ 10.6%
67.1B▲ 7.3%
76.59B▲ 14.1%
81.65B▲ 0%
Asset Turnover
4.34x4.46x4.58x4.29x3.73x4.22x4.19x4.38x4.20x4.23x
Asset Growth %
5.14%6.66%3.99%13.03%29.5%-1.36%10.6%7.26%14.14%53.07%
Total Current Liabilities
26.77B27.87B29.58B33.85B41.36B43.48B48.83B54.28B57.82B56.13B
Accounts Payable
25.4B26.84B28.39B31.71B38.01B40.19B45.84B50.94B54.72B51.88B
Days Payables Outstanding
62.2359.7959.1862.5266.7963.5165.7665.1864.1861.51
Short-Term Debt
12.12M151.66M139.01M593.85M475.56M1.23B823.81M781.1M371.56M202.66M
Deferred Revenue (Current)
0000000000
Other Current Liabilities
1.4B881.16M1.06B1.55B2.87B2.06B2.17B2.55B2.73B4.05B
Current Ratio
0.91x0.93x0.95x0.98x0.94x0.91x0.88x0.88x0.90x0.95x
Quick Ratio
0.48x0.50x0.58x0.60x0.57x0.52x0.52x0.53x0.55x0.59x
Cash Conversion Cycle
-9.6-8.65-10.95-10.21-8.42-8.02-11.6-11.23-11.49-9.18
Total Non-Current Liabilities
6.43B7.1B6.89B11.26B15.39B13.01B13.06B12.04B17.02B21.93B
Long-Term Debt
3.43B4.16B4.03B4B7.33B5.5B5.07B4.84B8.96B12.18B
Capital Lease Obligations
351.63M00385.51M946.15M864.29M924.25M1.03B1.42B1.42B
Deferred Tax Liabilities
2.49B1.83B1.86B686.49M1.69B1.62B1.66B1.64B1.62B6.62B
Other Non-Current Liabilities
159.66M409.95M382.89M6.19B5.43B5.03B5.41B4.52B5.03B8B
Total Liabilities
33.25B34.97B36.47B45.11B56.75B56.49B61.89B66.31B74.84B78.07B
Total Debt
3.79B4.66B4.49B4.98B8.75B7.59B6.82B6.65B10.75B12.39B
Net Debt
1.36B2.17B1.12B385.38M6.2B4.06B4.13B3.42B6.35B10.15B
Debt / Equity
1.79x1.53x1.50x-14.98x106.49x10.23x8.46x6.15x3.45x
Debt / EBITDA
1.55x2.17x1.91x2.05x2.75x2.20x1.99x1.60x2.28x2.46x
Net Debt / EBITDA
0.56x1.01x0.48x0.16x1.95x1.18x1.21x0.82x1.35x2.02x
Interest Coverage
7.16x7.21x5.95x-32.39x13.17x10.41x8.84x9.06x6.38x3.73x
Total Equity
2.11B▲ 0%
3.05B▲ 44.2%
2.99B▼ 1.9%
-839.64M▼ 128.1%
584.41M▲ 169.6%
71.27M▼ 87.8%
666.29M▲ 834.8%
786.74M▲ 18.1%
1.75B▲ 122.1%
3.58B▲ 0%
Equity Growth %
-0.7%44.24%-1.86%-128.05%169.6%-87.8%834.84%18.08%122.07%913.46%
Book Value per Share
9.5413.8414.13-4.102.800.343.263.938.9518.35
Total Shareholders' Equity
2.06B2.93B2.88B-1.02B223.35M-211.56M522M645.94M1.51B3.4B
Common Stock
2.81M2.84M2.85M2.88M2.91M2.93M2.95M2.96M2.97M2.98M
Retained Earnings
2.4B3.72B4.24B518.34M1.67B2.98B4.32B5.42B6.53B8.49B
Treasury Stock
-4.76B-5.43B-6.1B-6.51B-6.47B-7.02B-8.25B-9.82B-10.33B-10.44B
Accumulated OCI
-95.85M-79.25M-111.97M-108.83M-445.44M-1.83B-1.4B-989.12M-901.38M-961.31M
Minority Interest
0117.14M114.29M179.29M361.06M282.83M144.28M140.8M239.07M187.36M

COR Cash Flow Statement

Cencora, Inc. (COR) cash flow — operating, investing & free cash flow history

MetricSep'17Sep'18Sep'19Sep'20Sep'21Sep'22Sep'23Sep'24Sep'25TTM
Cash from Operations
1.49B1.41B2.34B2.21B2.67B2.7B3.91B3.48B3.88B2.28B
Operating CF Margin %
0.97%0.84%1.31%1.16%1.25%1.13%1.49%1.19%1.21%-
Operating CF Growth %
-53.15%-5.21%66.08%-5.84%20.82%1.37%44.7%-10.91%11.2%72.79%
Net Income
414.48M1.62B854.13M-3.4B1.54B1.67B1.75B1.52B1.57B2.55B
Depreciation & Amortization
432.33M510.11M497.51M408.01M514.79M709.84M980.85M448.2M01.06B
Stock-Based Compensation
62.21M62.32M58.87M74.41M99.59M93.4M124.62M148M089.24M
Deferred Taxes
319.07M-795.52M28.54M-1.54B334.87M196.18M-118.86M-102.32M0176.11M
Other Non-Cash Items
-141.1M189.31M541.59M4.75M-194.59M176.79M304.89M1.17B2.27B-121.01M
Working Capital Changes
402.02M-170.72M363.38M6.66B367.32M-139.66M874.54M298.69M35.42M-1.49B
Change in Receivables
-1.28B-657.77M-1.24B-1.63B-930.08M-1.66B-2.71B-2.78B-1.92B-2.01B
Change in Inventory
-431.45M-4.92M-167.99M-1.62B-1.12B-665.37M-2.18B-1.48B-1.27B-1.42B
Change in Payables
1.47B859.04M1.56B3.3B2.05B3.32B6.1B4.97B3.69B2.17B
Cash from Investing
-498.04M-1.11B-375.83M-379.87M-6.14B-368.44M-2.6B-618.1M-4.98B-5.73B
Capital Expenditures
-466.4M-336.41M-310.22M-369.68M-438.22M-496.32M-458.36M-487.17M-667.98M-718.02M
CapEx % of Revenue
0.3%0.2%0.17%0.19%0.2%0.21%0.17%0.17%0.21%0.22%
Acquisitions
-61.65M-785.3M-63.95M-56.08M-5.73B120.28M000-4.81B
Investments
----------
Other Investing
52.5M10.6M-1.66M-267.71M22.3M7.6M-2.14B-130.92M-4.31B-192.27M
Cash from Financing
-1.31B-242.87M-1.09B-603.62M1.95B-1.75B-2.22B-2.33B2.25B3.55B
Debt Issued (Net)
-749.55M635.7M-133.07M-32.01M2.22B-923.1M-623.26M-385.45M3.2B4.12B
Equity Issued (Net)
-227.01M-500.78M-597.8M-194.56M116.6M-389.79M-1.12B-1.45B-406.34M13.36M
Dividends Paid
-320.27M-333.04M-338.97M-343.58M-366.65M-391.69M-398.75M-416.17M-437.08M-458.98M
Share Repurchases
-329.93M-639.24M-674.03M-420.45M-82.15M-483.7M-1.18B-1.49B-435.47M0
Other Financing
-15.98M-44.75M-16.67M-33.47M-13.65M-48.2M-80.69M-75.85M-103.14M-118.83M
Net Change in Cash
-321.85M▲ 0%
57.4M▲ 117.8%
881.68M▲ 1436.0%
1.22B▲ 38.8%
-1.53B▼ 224.9%
523.41M▲ 134.3%
-840.65M▼ 260.6%
544.99M▲ 164.8%
1.1B▲ 101.2%
19.29M▲ 0%
Free Cash Flow
1.02B▲ 0%
1.07B▲ 5.1%
2.03B▲ 89.2%
1.84B▼ 9.7%
2.23B▲ 21.3%
2.21B▼ 1.0%
3.45B▲ 56.5%
3B▼ 13.2%
3.21B▲ 7.0%
1.56B▲ 0%
FCF Margin %
0.67%0.64%1.13%0.97%1.04%0.92%1.32%1.02%1%0.47%
FCF Growth %
-62.32%5.12%89.19%-9.66%21.28%-0.97%56.47%-13.19%6.99%-56.42%
FCF per Share
4.614.889.608.9710.6910.4516.8814.9716.437.97
FCF Conversion (FCF/Net Income)
3.59x0.85x2.74x-0.65x1.73x1.59x2.24x2.31x2.49x0.61x
Interest Paid
0000000000
Taxes Paid
0000000000

COR Key Ratios

Cencora, Inc. (COR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
19.53%64.22%28.31%-315.71%263.5%518.18%473.26%207.72%122.67%105.78%
Return on Invested Capital (ROIC)
41.34%28.49%30%83.01%63.34%37.81%41.13%50.65%44.45%31.39%
Gross Margin
2.71%2.45%2.52%2.52%2.93%3.19%2.96%2.96%3.16%3.55%
Net Margin
0.27%0.99%0.48%-1.79%0.72%0.71%0.67%0.51%0.48%0.78%
Debt / Equity
1.79x1.53x1.50x-14.98x106.49x10.23x8.46x6.15x3.45x
Interest Coverage
7.16x7.21x5.95x-32.39x13.17x10.41x8.84x9.06x6.38x3.73x
FCF Conversion
3.59x0.85x2.74x-0.65x1.73x1.59x2.24x2.31x2.49x0.61x
Revenue Growth
4.29%9.66%6.94%5.74%12.69%11.5%9.89%12.12%9.31%5.95%
Related:COR Dividend History·COR Revenue History·COR Price History·COR P/E History·COR Financial Ratios·COR Institutional Holders

COR SEC Filings & Documents

Cencora, Inc. (COR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Mar 23, 2026·SEC

Material company update

Mar 17, 2026·SEC

10-K Annual Reports

1
FY 2025

Nov 25, 2025·SEC

10-Q Quarterly Reports

5
FY 2026

May 6, 2026·SEC

FY 2026

Feb 4, 2026·SEC

FY 2025

Aug 6, 2025·SEC

COR Frequently Asked Questions

Cencora, Inc. (COR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Cencora, Inc. (COR) reported $328.68B in revenue for fiscal year 2025. This represents a 5820% increase from $5.55B in 1996.

Cencora, Inc. (COR) grew revenue by 9.3% over the past year. This is steady growth.

Yes, Cencora, Inc. (COR) is profitable, generating $2.55B in net income for fiscal year 2025 (0.5% net margin).

Dividend & Returns

Yes, Cencora, Inc. (COR) pays a dividend with a yield of 0.82%. This makes it attractive for income-focused investors.

Cencora, Inc. (COR) has a return on equity (ROE) of 122.7%. This is excellent, indicating efficient use of shareholder capital.

Cencora, Inc. (COR) generated $1.56B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in COR back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

How much would $100/month in COR be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →